The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine

Molecular Pharmacology

Volumn 72, Issue 3, 2007, Pages 536-544

  Lam, Wing ^a   Leung, Chung Hang ^a   Bussom, Scott ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLOXALLYL GLYCINE; DNA; GEMCITABINE; GLYCINE DERIVATIVE; PHOSPHOGLYCERATE KINASE; TROXACITABINE; UNCLASSIFIED DRUG;

ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOSINE; DEOXYCYTIDINE; DIOXOLANES; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; HUMANS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; PHOSPHOGLYCERATE KINASE; RHABDOMYOSARCOMA;

EID: 34548313707     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.033472     Document Type: Article

References (33)

1. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, and Ueda R (2004) Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 95:753-757.
2. Brown JM and Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447.
3. Casanello P, Torres A, Sanhueza F, Gonzalez M, Farias M, Gallardo V, Pastor-Anglada M, San Martin R and Sobrevia L (2005) Equilibrative nucleoside transporter 1 expression is downregulated by hypoxia in human umbilical vein endothelium. Circ Res 97:16-24.
4. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, Kardia SL, Iannettoni MD, Yee J, Hogg PJ, Orringer MB, Hanash SM, and Beer DG (2003) Protein profiles associated with survival in lung adenocarcinoma Proc Natl Acad Sci U S A 100:13537-13542.
5. Chou KM, Kukhanova M, and Cheng YC (2000) A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. J Biol Chem 275:31009-31015.
6. Daly EB, Wind T, Jiang XM, Sun L, and Hogg PJ (2004) Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochim Biophys Acta 1691:17-22.
7. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C, Loffler M, Reyes G, Duszenko M, Karhausen J, Robinson A, Westerman KA, Coe IR, and Colgan SP (2005) HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 202:1493-1505.
8. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, and Kantarjian HM (2002) Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 20:656-664.
9. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, and Danesi R (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66:3928-3935.
10. Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, Lee N, Mackey JR, Young JD, Jolivet J, Lafreniere RG, and Cass CE (2001) Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 61:7217-7224.
11. Gourdeau H, Leblond L, Hamelin B, Dong K, Ouellet F, Boudreau C, Custeau D, Richard A, Gilbert MJ, and Jolivet J (2004) Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development. Clin Cancer Res 10:7692-7702.
12. Grove KL and Cheng YC (1996) Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res 56:4187-4191.
13. Grove KL, Guo X, Liu SH, Gao Z, Chu CK, and Cheng YC (1995) Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 55:3008-3011.
14. Hatzis P, Al-Madhoon AS, Jullig M, Petrakis TG, Eriksson S, and Talianidis I (1998) The intracellular localization of deoxycytidine kinase. J Biol Chem 273:30239-30243.
15. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, and Kaspers GJ (2005) The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 93:1388-1394.
16. Hwang TL, Liang Y, Chien KY, and Yu JS (2006) Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 6:2259-2272.
17. Kim HO, Shanmiganathan K, Alves AJ, Jeong LS, Beach JW, Schinazi RF, Chang CN, Cheng YC, and Chu CK (1992) Potent anti-HIV and anti-HBV activities of (-)-L-β-dioxolane-C and (+)-D-β-dioxolane-T and their asymmetric syntheses. Tetrahedron Lett 33:6899-6902.
18. King KM, Damaraju VL, Vickers MF, Yao SY, Lang T, Tackaberry TE, Mowles DA, Ng AM, Young JD, and Cass CE (2006) A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 69:346-353.
19. Kong W, Engel K, and Wang J (2004) Mammalian nucleoside transporters. Curr Drug Metab 5:63-84.
20. Kress S, Stein A, Maurer P, Weber B, Reichert J, Buchmann A, Huppert P, and Schwarz M (1998) Expression of hypoxia-inducible genes in tumor cells. J Cancer Res Clin Oncol 124:315-320.
21. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, and Cheng YC (2002a) Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem 277:5453-5459.
22. Krishnan P, Liou JY, and Cheng YC (2002b) Phosphorylation of pyrimidine L-deoxynucleoside analog diphosphates. Kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphosphates by 3-phosphoglycerate kinase. J Biol Chem 277:31593-31600.
23. Krishnan P, Gullen EA, Lam W, Dutschman GE, Grill SP, and Cheng YC (2003) Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J Biol Chem 278:36726-36732.
24. Kukhanova M, Liu SH, Mozzherin D, Lin TS, Chu CK, and Cheng YC (1995) L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J Biol Chem 270:23055-23059.
25. Lam W, Park SY, Leung CH, and Cheng YC (2006) Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and β-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and β-D-arabinofuranosylcytosine). Mol Pharmacol 69:1607-1614.
26. Lapointe R, Letourneau R, Steward W, Hawkins RE, Batist G, Vincent M, Whittom R, Eatock M, Jolivet J, and Moore M (2005) Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors. Ann Oncol 16:289-293.
27. Liou JY, Dutschman GE, Lam W, Jiang Z, and Cheng YC (2002) Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res 62:1624-1631.
28. Marcé S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M, and Colomer D (2006) Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91:895-902.
29. Okino ST, Chichester CH, and Whitlock JP Jr. (1998) Hypoxia-inducible mammalian gene expression analyzed in vivo at a TATA-driven promoter and at an initiator-driven promoter. J Biol Chem 273:23837-23843.
30. Patel PH, Chadalavada RS, Chaganti RS, and Motzer RJ (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12:7215-7220.
31. Podgorska M, Kocbuch K, and Pawelczyk T (2005) Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 52:749-758.
32. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, and Mackey JR (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10:6956-6961.
33. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, and Koay ES (2005) Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4:1686-1696.